Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE REGIMEN: Abrocitinib Maintenance in Atopic Dermatitis
NCT03627767Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Started Jun 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03627767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627767.